Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rocio Tamayo, Bermejo"'
Publikováno v:
Can J Hosp Pharm
Background: Real-world data are critical to demonstrate the reproducibility of evidence and the external generalizability of randomized clinical trials. Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4/6 that has been sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ec21a16ca0c11d1ce68ddf36c1b476
https://www.cjhp-online.ca/index.php/cjhp/article/download/3252/4640
https://www.cjhp-online.ca/index.php/cjhp/article/download/3252/4640
Autor:
Rocio Tamayo-Bermejo, Juan Carlos del Rio-Valencia, Beatriz Mora-Rodriguez, Isabel Muñoz-Castillo
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction Immunotherapy has become a standard treatment for lung cancer; the objective of this study was to evaluate the effectiveness, safety of pembrolizumab monotherapy in patients with advanced or metastatic non-small-cell lung cancer used in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3bfd299f729844aaf49ba7e136ff1d1
https://pubmed.ncbi.nlm.nih.gov/34931913
https://pubmed.ncbi.nlm.nih.gov/34931913
Autor:
Beatriz Mora Rodríguez, Rocio Tamayo-Bermejo, Juan Carlos Del Rio-Valencia, Casillo-Muñoz Isabel
Introduction: Immunotherapy has become a standard treatment for lung cancer; the objective of this study was to evaluate the effectiveness, safety of pembrolizumab monotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9b9c2654de2523bc5c80ac72fdcc6dd
https://doi.org/10.22541/au.159957150.04571440
https://doi.org/10.22541/au.159957150.04571440
Autor:
Rocio Tamayo-Bermejo, Laura González-Díaz, Maria Eva Mingot-Castellano, Anabel I. Heiniger-Mazo
Publikováno v:
Blood Coagulation & Fibrinolysis. 26:509-514
There is no clear consensus on the best practice for long-term prophylaxis in adults with severe haemophilia A. This is a single-centre prospective case series study. We describe here the demographic data, type and reason of prophylaxis in adult pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40f7080a079c964d0ae0ece84666c56
https://doi.org/10.1097/mbc.0000000000000261
https://doi.org/10.1097/mbc.0000000000000261
Autor:
Ana Isabel Heiniger-Mazo, Rocio Tamayo-Bermejo, Dana Diaz-Canales, Maria Eva Mingot-Castellano
Publikováno v:
Blood. 124:1502-1502
BACKGROUND: Replacement therapy with factor VIII (FVIII) in patients with severe hemophilia A has a high cost. To optimize this consumption without an increase in bleeding events or a delay in the recovery of these bleeds is a question of great inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdf4102793b2bffe9c90b659fb1bbaef
https://doi.org/10.1182/blood.v124.21.1502.1502
https://doi.org/10.1182/blood.v124.21.1502.1502
Autor:
Rocio Tamayo-Bermejo, Laura González-Díaz, Maria Eva Mingot-Castellano, Ana Isabel Heiniger-Mazo
Publikováno v:
Blood. 124:5052-5052
Background: Prophylaxis is the treatment of choice in patients with severe hemophilia A to prevent the development of haemophilic arthropathy and to preserve musculoskeletal function. In adult patients, there is no defined consensus on the indication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ce962e9e27a889112d013d4f1506f41
https://doi.org/10.1182/blood.v124.21.5052.5052
https://doi.org/10.1182/blood.v124.21.5052.5052